The Leaf Index
Vol. IA field guide to cannabis cultivarsleafly.cc
No. 3767Indica

Avidekel

Unknown

Avidekel is a distinguished indica-dominant cultivar recognized for its exceptionally high CBD content and ultra-low THC levels, making it ideal for medical users. Developed to provide therapeutic benefits without significant psychoactive effects, this strain offers a consistent profile favored for daytime use and for individuals sensitive to THC.

EffectsCalm Focused
AromaHerbalEarthyPineCitrusPepperWoody

Appearance and Morphology

Avidekel plants typically exhibit indica-dominant traits, characterized by a compact structure, broad leaves, and closely spaced nodes. Indoor cultivation often results in plants around 90-120 cm tall, while outdoor plants can reach up to 200 cm. The buds are known for being dense and resinous, with a compact calyx structure and minimal fox-tailing under stable conditions. They usually display forest-green hues, accented by orange or amber pistils and moderate sugar leaf coverage.

Aroma and Flavor Profile

The aroma of Avidekel is predominantly herbal and earthy, with noticeable pine notes and subtle undertones of pepper and citrus. Upon closer inspection, woody and fresh scents, reminiscent of a conifer grove, can be detected. The flavor profile mirrors its aroma, offering earthy, piney, and slightly peppery tastes. The initial inhale is smooth and herbal, often with a hint of citrus or a cooling sensation from pinene, while the exhale carries a warm spiciness.

Cannabinoid and Terpene Profile

Avidekel is specifically bred for a high CBD to low THC ratio, often exceeding 15:1 and sometimes reaching over 25:1. Lab-tested dried flower typically shows CBD content between 12-20% and THC levels below 1.2%. The terpene profile is led by myrcene, beta-caryophyllene, and alpha-pinene, contributing to its earthy, peppery, and pine-like aromatic and flavor characteristics. Other terpenes like linalool, humulene, terpinolene, ocimene, and guaiol may also be present.

Effects and Therapeutic Potential

This strain is sought after for its ability to provide calming and focused effects without significant intoxication, making it suitable for daytime use. Avidekel is often utilized by patients managing conditions such as anxiety, inflammation, and pain. Its high CBD content is particularly noted for its potential therapeutic applications in these areas, aligning with preferences for CBD-dominant ratios in medical cannabis.

Growing Characteristics

Avidekel is considered grower-friendly, producing uniform phenotypes that contribute to consistent results. It has an average flowering period of 8-9 weeks, with some phenotypes finishing as early as 56 days. Indoor yields can range from 400-550 grams per square meter, while outdoor yields can be between 600-1200 grams per plant. The plants respond well to training techniques like topping and scrogging.

Origins and Development

Avidekel was originally developed in Israel in the early 2010s by the medical cannabis company Tikun Olam. The primary objective was to create a stable, high-CBD, low-THC strain for medical patients who required therapeutic effects without the psychoactive experience of THC. This initiative was part of Israel's early structured medical cannabis program, which fostered breeding for specific medical endpoints and clinical observation.

Frequently asked questions

What is Avidekel known for?
Avidekel is known for its high CBD and ultra-low THC content, making it a preferred choice for medical use without significant psychoactive effects.
What are the typical cannabinoid ratios in Avidekel?
Avidekel commonly exhibits CBD:THC ratios exceeding 15:1, often reaching 25:1 or higher, with CBD levels typically in the mid to high teens and THC below 1.2%.
What kind of effects does Avidekel produce?
Users report calming and focused effects from Avidekel, suitable for daytime use and managing conditions without impairment.
Who developed the Avidekel strain?
Avidekel was developed in Israel by the pioneering medical cannabis company Tikun Olam in the early 2010s.